{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:40:11Z","timestamp":1782960011741,"version":"3.54.5"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11-12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Psoriasis and atopic dermatitis are chronic, immune-mediated skin disorders that are disqualifying for entrance into the military. Both conditions can cause difficulty wearing body armor and other protective equipment when poorly controlled, limiting a service member\u2019s ability to train and deploy worldwide. In addition, these conditions may be exacerbated by military service because of increased exposure to austere environments, extreme temperatures, stress, skin injury, bug bites, and vaccinations Service members have limited treatment options because of restrictions on systemic medications that can be used while deployed. Newer systemic medications\u2014in particular, biologics and oral immunomodulators\u2014have evolved to be both extremely effective and safe. We review more recent treatment options for psoriasis and atopic dermatitis in the context of DoD\u2019s regulations guiding entry and retention of personnel with psoriasis and eczema and make recommendations regarding updating DoD policy for systemic treatment options.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A literature search was performed using PubMed, Embase, and Ovid with the last search done in the fall of 2023 from all years to date. These articles were further screened based on inclusion and exclusion criteria. In total, 25 articles were included in this review. An Internet search was also performed on the DoD\u2019s regulations guiding entry and retention of personnel with psoriasis and eczema. In addition, we examined medical requirements for deployment to the U.S. Central Command and U.S. European Command.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Currently, U.S. Central Command and U.S. European Command do not allow the use of medications with special storage and handling requirements on deployments. Newer biologics are safe and efficacious but require refrigeration, although other immunomodulators like deucravacitinib and apremilast are oral pills and do not have cold-storage requirements. However, the use of biologics in austere environments may be feasible because of increased intervals between dosing and the ability to store refrigerated medical supplies in most deployed environments. For military service members with psoriasis, risankizumab and deucravacitinib are excellent options given their favorable safety and efficacy profiles. Of the biologics available for atopic dermatitis, dupilumab is the safest and effective systemic medication available. The Janus kinase inhibitors have also demonstrated excellent efficacy in treating atopic dermatitis, but more safety data are needed because of potential adverse events to include heart-related events, blood clots, and cancers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Systemic treatments have evolved to become highly specific for both eczema and psoriasis. These newer biologics and immunomodulators may be compatible with use in the deployed setting, especially those that have long dosing intervals and proven efficacy and safety. Of the biologics, dupilumab and risankizumab offer the best efficacy, safety, and dosing intervals for atopic dermatitis and psoriasis, respectively. Deucravcitinib is a recently FDA-approved oral immunomodulator for psoriasis that has an excellent safety profile and efficacy. Allowing the use of these medications on deployments will enable more people with moderate to severe psoriasis and eczema to join and remain in the military while receiving effective treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usae139","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T16:55:19Z","timestamp":1712940919000},"page":"e2374-e2381","source":"Crossref","is-referenced-by-count":2,"title":["Reappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0220-7121","authenticated-orcid":false,"given":"Alexius","family":"Russell","sequence":"first","affiliation":[{"name":"School of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Williamson","sequence":"additional","affiliation":[{"name":"School of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, William Beaumont Army Medical Center , El Paso, TX 48073,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunghun","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"2024110620115470800_R1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.12788\/cutis.0723","article-title":"Dermatologic implications of sleep deprivation in the US military","volume":"111(3)","author":"Anderson","year":"2023","journal-title":"Cutis"},{"key":"2024110620115470800_R2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","article-title":"Atopic dermatitis: pathophysiology","volume":"1027","author":"David Boothe","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"2024110620115470800_R3","article-title":"StatPearls","author":"Nemeth","year":"2022"},{"key":"2024110620115470800_R4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/cea.14276","article-title":"Trends in eczema prevalence in children and adolescents: a Global Asthma Network Phase I Study","volume":"53(3)","author":"Langan","year":"2023","journal-title":"Clin Exp Allergy"},{"issue":"8 Suppl","key":"2024110620115470800_R5","first-page":"s216","article-title":"Psoriasis and psoriatic arthritis overview","volume":"22","author":"Menter","year":"2016","journal-title":"Am J Manag Care"},{"issue":"1","key":"2024110620115470800_R6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12659\/PJR.883763","article-title":"Psoriatic arthritis","volume":"78","author":"Sankowski","year":"2013","journal-title":"Pol J Radiol"},{"issue":"5","key":"2024110620115470800_R7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"3","key":"2024110620115470800_R8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"9","key":"2024110620115470800_R9","first-page":"532","article-title":"Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis","volume":"43","author":"D\u2019Ippolito","year":"2018","journal-title":"Pharm Ther"},{"issue":"3","key":"2024110620115470800_R10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2024110620115470800_R11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","article-title":"Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score\u2013matched cohort study","volume":"84","author":"Schneeweiss","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2024110620115470800_R12","first-page":"3","article-title":"Seeing Red with Dupilumab","volume":"5","author":"Heymann","year":"2023","journal-title":"Am Acad Dermatol"},{"issue":"12","key":"2024110620115470800_R13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"JADE COMPARE investigators. Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"2024110620115470800_R14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"11","key":"2024110620115470800_R15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/14712598.2020.1822813","article-title":"Update on risankizumab for the treatment of moderate to severe psoriasis","volume":"20","author":"Al-Janabi","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"2024110620115470800_R16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"2024110620115470800_R17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","article-title":"Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review","volume":"23","author":"Masson Regnault","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2024110620115470800_R18","first-page":"221","article-title":"Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL","volume":"17","author":"Stein Gold","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"2024110620115470800_R19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jdv.14738","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","volume":"32","author":"Reich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2024110620115470800_R20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jaad.2017.09.067","article-title":"Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study","volume":"78","author":"Ighani","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024110620115470800_R21","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1136\/annrheumdis-2022-eular.1377","article-title":"AB0890\u2005Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","volume":"81(Suppl 1)","author":"Warren","year":"2022","journal-title":"Ann Rheumatic Dis"},{"issue":"6","key":"2024110620115470800_R22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2024110620115470800_R23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"ORAL surveillance investigators. cardiovascular and cancer risk with tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2024110620115470800_R24","article-title":"Department of Defense Instruction 6130.03 Volume 2","author":"U.S. Department of Defense"},{"issue":"10","key":"2024110620115470800_R25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2024110620115470800_R26","article-title":"Department of Defense Instruction 6130.03 Volume 1","author":"U.S. Department of Defense"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/189\/11-12\/e2374\/60454223\/usae139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/189\/11-12\/e2374\/60454223\/usae139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T20:12:02Z","timestamp":1730923922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/189\/11-12\/e2374\/7644863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":26,"journal-issue":{"issue":"11-12","published-online":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usae139","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,4,12]]}}}